 |
| Shingrix, GlaxoSmithKline's new Shingles vaccine |
Just three business days after receiving the stamp of approval from federal regulators, a more effective shingles vaccine will receive the attention of the Centers for Disease Control on Wednesday, when a vote is expected about recommending its use to the general public.
The CDC's Advisory Committee on Immunization Practices will discuss how to add Shingrix, which was approved late Friday by the Food and Drug Administration, to its Adult Immunization Schedule. The vaccine will find its place among other recommended vaccines and shots, with this particular medicine slated for adults 50 and older, according to its maker GlaxoSmithKline. The CDC, however, says the vaccine is best suited for adults 60 and older because its potency can weaken over time.
Wednesday's committee meeting also spotlights the schedule itself, providing an opportunity to raise it especially given that many middle-aged adults are likely unaware even of its existence. So here it is, and here's the link to the CDC's website if you'd like more detail on each of the vaccines listed on the left.........To Read More....
Wednesday's committee meeting also spotlights the schedule itself, providing an opportunity to raise it especially given that many middle-aged adults are likely unaware even of its existence. So here it is, and here's the link to the CDC's website if you'd like more detail on each of the vaccines listed on the left.........To Read More....
No comments:
Post a Comment